High TPMT enzyme activity does not explain drug resistance due to preferential 6‐methylmercaptopurine production in patients on thiopurine treatment

Overview of attention for article published in Alimentary Pharmacology & Therapeutics, April 2012

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (72nd percentile)
Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

guideline: 2 clinical guideline sources

Readers on

mendeley: 30 Mendeley

So far, Altmetric has seen 2 Guidelines that reference this research output.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update

Clinical guideline published by Clinical Pharmacogenetics Implementation Consortium (CPIC) on 31 Jan 2026

The Clinical Pharmacogenetics Implementation Consortium (CPIC) is an international group dedicated to enhancing the use of pharmacogenetic testing in clinical settings. They develop and share peer-reviewed, evidence-based guidelines to aid healthcare providers in making informed prescribing decisions based on genetic test results.

Pharmacogenetics of immunosuppressants: State of the art and clinical implementation – recommendations from the French National Network of Pharmacogenetics (RNPGx)

Clinical guideline published by French National Network of Pharmacogenetics (RNPGx) on 30 Jan 2017

The French National Network of Pharmacogenetics (RNPGx) focuses on integrating pharmacogenetic testing into clinical practice. It provides evidence-based guidelines for genetic testing, emphasizing the impact of genetic variants on drug efficacy and safety, and offers specific recommendations for various medical conditions.

This page shows the most recent posts that mention this research output. Click here to find out how to access more activity.